Uber found not liable in first US trial over driver sexual assault claims

Jean-Charles Naouri, the former CEO of Casino Guichard Perrachon SA, is facing serious allegations of stock price manipulation as he stands trial in Paris. This case is significant as it highlights the ongoing scrutiny of corporate governance and market practices in France, raising concerns about accountability in the financial sector.

In a recent ruling, a jury found Uber not responsible for a sex assault case, raising concerns about the safety of passengers using ride-sharing services. This decision comes amid a growing number of similar lawsuits against the company, highlighting the ongoing debate over accountability in the gig economy. As more victims come forward, the implications of this ruling could affect public trust in ride-sharing platforms and prompt discussions about necessary safety measures.

Mizuho has started coverage of Uber's stock with an 'Outperform' rating and a target price of $130. This is significant as it reflects confidence in Uber's growth potential and market position, suggesting that investors might see a favorable return on their investment. Mizuho's endorsement could attract more attention to Uber's stock, potentially driving up its value.

Anteris Technologies has received a significant boost as global shareholders approved a waiver from the Australian Securities Exchange (ASX), allowing the company to move forward with its clinical trials. This approval is crucial as it paves the way for Anteris to advance its innovative medical solutions, which could have a substantial impact on patient care. The trial update indicates progress in their research, highlighting the company's commitment to improving healthcare outcomes.

The UK's FTSE 100 index has reached a record high, marking a significant milestone as investors remain optimistic despite concerns over a potential US government shutdown. This surge comes as global stocks celebrate their best September performance since 2013, reflecting a resilient market sentiment. The rise in the FTSE 100 is particularly noteworthy given the backdrop of declining business confidence in the UK and a contraction in the eurozone's manufacturing sector. This positive trend in the stock market is crucial as it indicates investor confidence and economic stability, which can lead to further investments and growth.

PPE Medpro, a company linked to Baroness Mone, has been ordered by the court to repay £122 million in damages related to a PPE contract. This ruling highlights the ongoing scrutiny of government contracts and the accountability of companies involved in public health procurement, especially in the wake of the pandemic.

Greggs has announced another price increase for its breakfast meal deals and biscuits due to ongoing cost pressures. This move is significant as it reflects the broader trend of rising prices in the food industry, which could impact consumer spending and dining habits. Customers may need to adjust their budgets as they face higher costs for their favorite meals.

Gold Royalty has successfully expanded its portfolio to include 250 assets following a significant deal involving the Spanish Moon project. This expansion is crucial as it not only enhances the company's asset base but also positions it for greater opportunities in the gold market, reflecting a strong growth strategy that could benefit investors and stakeholders alike.

DuPont has announced the final results of its exchange offers for senior notes, marking a significant step in its financial strategy. This move is important as it reflects the company's efforts to manage its debt and optimize its capital structure, which can ultimately impact its financial health and investor confidence.

In response to looming tariff threats, global drugmakers are rapidly increasing their presence in the U.S. market. This move is significant as it not only reflects the companies' commitment to maintaining access to one of the largest pharmaceutical markets but also highlights the ongoing shifts in global trade dynamics. By bolstering their operations in the U.S., these companies aim to mitigate potential impacts from tariffs, ensuring they can continue to deliver essential medications to American consumers.